Cargando…
Anti-PD-1 sintilimab-induced bilateral optic neuropathy in non-small cell lung cancer: A case report and literature review
Anti-PD-1/PD-L1 immunotherapy reactivates T-cell activity to boost the antitumor effect and may trigger autoimmune toxicity in various organ systems involving eyeball and periocular structures at the same time. The rarity of ocular immune-related adverse events should not prevent us from paying atte...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9396260/ https://www.ncbi.nlm.nih.gov/pubmed/36016624 http://dx.doi.org/10.3389/fonc.2022.931074 |
_version_ | 1784771890792890368 |
---|---|
author | Wang, Jian Xiao, Xiaoyue Dong, Xiaorong Wu, Gang Wang, Xinghua Zhang, Ruiguang |
author_facet | Wang, Jian Xiao, Xiaoyue Dong, Xiaorong Wu, Gang Wang, Xinghua Zhang, Ruiguang |
author_sort | Wang, Jian |
collection | PubMed |
description | Anti-PD-1/PD-L1 immunotherapy reactivates T-cell activity to boost the antitumor effect and may trigger autoimmune toxicity in various organ systems involving eyeball and periocular structures at the same time. The rarity of ocular immune-related adverse events should not prevent us from paying attention to this issue because of the bad consequences of visual impairment. This is the first case report of anti-PD-1 sintilimab-induced bilateral optic neuropathy in a 76-year-old man with squamous non-small cell lung cancer (NSCLC). The patient presented with sudden vision blurring without pain in both eyes after three therapeutic cycles of sintilimab plus chemotherapy. Based on the ophthalmic examination, laboratory, and radiological results, our patient was diagnosed with optic neuropathy complication secondary to anti-PD-1 sintilimab treatment. Consequently, sintilimab was held and systemic steroids were administered. The follow-up review showed that the vision recovered and the size of the primary tumor continued to decrease with the response assessment as the partial response. In conclusion, this case report suggested that patients with NSCLC undergoing anti-PD-1/PD-L1 therapy should be closely monitored for ophthalmic assessment and alert to the occurrence of sintilimab-induced optic neuropathy. |
format | Online Article Text |
id | pubmed-9396260 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-93962602022-08-24 Anti-PD-1 sintilimab-induced bilateral optic neuropathy in non-small cell lung cancer: A case report and literature review Wang, Jian Xiao, Xiaoyue Dong, Xiaorong Wu, Gang Wang, Xinghua Zhang, Ruiguang Front Oncol Oncology Anti-PD-1/PD-L1 immunotherapy reactivates T-cell activity to boost the antitumor effect and may trigger autoimmune toxicity in various organ systems involving eyeball and periocular structures at the same time. The rarity of ocular immune-related adverse events should not prevent us from paying attention to this issue because of the bad consequences of visual impairment. This is the first case report of anti-PD-1 sintilimab-induced bilateral optic neuropathy in a 76-year-old man with squamous non-small cell lung cancer (NSCLC). The patient presented with sudden vision blurring without pain in both eyes after three therapeutic cycles of sintilimab plus chemotherapy. Based on the ophthalmic examination, laboratory, and radiological results, our patient was diagnosed with optic neuropathy complication secondary to anti-PD-1 sintilimab treatment. Consequently, sintilimab was held and systemic steroids were administered. The follow-up review showed that the vision recovered and the size of the primary tumor continued to decrease with the response assessment as the partial response. In conclusion, this case report suggested that patients with NSCLC undergoing anti-PD-1/PD-L1 therapy should be closely monitored for ophthalmic assessment and alert to the occurrence of sintilimab-induced optic neuropathy. Frontiers Media S.A. 2022-08-09 /pmc/articles/PMC9396260/ /pubmed/36016624 http://dx.doi.org/10.3389/fonc.2022.931074 Text en Copyright © 2022 Wang, Xiao, Dong, Wu, Wang and Zhang https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Oncology Wang, Jian Xiao, Xiaoyue Dong, Xiaorong Wu, Gang Wang, Xinghua Zhang, Ruiguang Anti-PD-1 sintilimab-induced bilateral optic neuropathy in non-small cell lung cancer: A case report and literature review |
title | Anti-PD-1 sintilimab-induced bilateral optic neuropathy in non-small cell lung cancer: A case report and literature review |
title_full | Anti-PD-1 sintilimab-induced bilateral optic neuropathy in non-small cell lung cancer: A case report and literature review |
title_fullStr | Anti-PD-1 sintilimab-induced bilateral optic neuropathy in non-small cell lung cancer: A case report and literature review |
title_full_unstemmed | Anti-PD-1 sintilimab-induced bilateral optic neuropathy in non-small cell lung cancer: A case report and literature review |
title_short | Anti-PD-1 sintilimab-induced bilateral optic neuropathy in non-small cell lung cancer: A case report and literature review |
title_sort | anti-pd-1 sintilimab-induced bilateral optic neuropathy in non-small cell lung cancer: a case report and literature review |
topic | Oncology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9396260/ https://www.ncbi.nlm.nih.gov/pubmed/36016624 http://dx.doi.org/10.3389/fonc.2022.931074 |
work_keys_str_mv | AT wangjian antipd1sintilimabinducedbilateralopticneuropathyinnonsmallcelllungcanceracasereportandliteraturereview AT xiaoxiaoyue antipd1sintilimabinducedbilateralopticneuropathyinnonsmallcelllungcanceracasereportandliteraturereview AT dongxiaorong antipd1sintilimabinducedbilateralopticneuropathyinnonsmallcelllungcanceracasereportandliteraturereview AT wugang antipd1sintilimabinducedbilateralopticneuropathyinnonsmallcelllungcanceracasereportandliteraturereview AT wangxinghua antipd1sintilimabinducedbilateralopticneuropathyinnonsmallcelllungcanceracasereportandliteraturereview AT zhangruiguang antipd1sintilimabinducedbilateralopticneuropathyinnonsmallcelllungcanceracasereportandliteraturereview |